Study on the effect of oligofructose-enriched inulin in type 2 diabetes

Study on the comprasion of the effect of oligofructose-enriched inulin with maltodextrin (placebo) on some immunologic,inflammatory and anti-inflammatory factors in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201203103565N4

Enrollment

Registered

2012-03-27

Start date

2012-02-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: Oligofructose-enriched inulin powder 10 g /d, divided into 2 portions of 5g each to be eaten during breakfast and dinner, for two months. Intervention 2: Control gr

Treatment - Drugs

Placebo

Intervention group: Oligofructose-enriched inulin powder 10 g /d, divided into 2 portions of 5g each to be eaten during breakfast and dinner, for two months

Control group: dextrin maltose 10 g /d, divided into 2 portions of 5g each to be eaten during breakfast and dinner, for two months

Eligibility

Sex/Gender

Female

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 30-65 years old, having diabetes at least 6 months prior to the study, consumption of blood glucose lowering drug,. typical ?ber intake <25 g ?ber/d and inulin fructans intake =200 g ?ber/d. Exclusion criteria: consumption of antioxidants supplements during last 3 months prior to the study, using insulin, pregnancy, lactation, acute renal disease,liver disease,hyperthyroidism and hypothyroidism,heart disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CD4/CD8?CD3?CD4?CD8?CD11b. Timepoint: Baseline,The end of the second month. Method of measurement: Flow cytometry.;IFN-?,IL12. Timepoint: Baseline,The end of the second month. Method of measurement: Elisa.;IL4. Timepoint: Baseline,The end of the second month. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Weight,height,BMI,WHR,WC. Timepoint: Baseline,The end of second month. Method of measurement: Antropometric Methods.;TC?TG?HDL?LDL. Timepoint: Baseline,The end of second month. Method of measurement: calorimetric.;FBS,HbA1C. Timepoint: Baseline,The end of second month. Method of measurement: calorimetric.;Blood pressure. Timepoint: Baseline,The end of second month. Method of measurement: Mercury pressure measurement.	—

Measure

Time frame

Weight,height,BMI,WHR,WC. Timepoint: Baseline,The end of second month. Method of measurement: Antropometric Methods.;TC?TG?HDL?LDL. Timepoint: Baseline,The end of second month. Method of measurement: calorimetric.;FBS,HbA1C. Timepoint: Baseline,The end of second month. Method of measurement: calorimetric.;Blood pressure. Timepoint: Baseline,The end of second month. Method of measurement: Mercury pressure measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farnaz Tavakkoli

Faculty Of Medicine, Tabriz University Of Medical Sciences

farnaz_tavakkoli62@yahoo.com+98 41 1336 4667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026